In Malaysia, drug safety is evaluated by the National Pharmaceutical Regulatory Agency (NPRA) through a rigorous process involving pre-clinical and clinical trials, assessment of manufacturing practices, and post-marketing surveillance. The evaluation ensures compliance with international standards, focusing on efficacy, quality, and safety before granting approval for public use.